HER2 status-Negative Posts on Medivizor
Navigation Menu

HER2 status-Negative Posts on Medivizor

On Living with Breast Cancer: Dr. Kelly Shanahan’s Patient Journey Part 2

On Living with Breast Cancer: Dr. Kelly Shanahan’s Patient Journey Part 2

Posted by on Mar 30, 2018 in Blog, Breast cancer | 4 comments

In From Physician to Patient, I introduced Dr. Kelly Shanahan, a mother, wife, and obstetrician-gynecologist living and working in California. Her life changed with a breast cancer diagnosis. “In 2008, I was diagnosed with early stage breast cancer, stage IIB to be exact. I underwent an aggressive bilateral mastectomy, because   1) as an ob/gyn...

Read More

Endocrine therapy used with targeted therapy is associated with similar quality of life in comparison to endocrine therapy used alone.

Posted by on Feb 12, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to find out if endocrine therapy (ET) is best used alone or with targeted therapy in the treatment of hormone positive, HER2 negative advanced breast cancer. The study found that patients who used ET and targeted therapy together experienced a better quality of life in some regards compared to ET used alone.  Some...

Read More

Endocrine therapy and targeted therapy are safe for patients over 65 with HR+/HER2- advanced breast cancer

Posted by on Dec 30, 2017 in Breast cancer | 0 comments

In a nutshell This study aimed to evaluate the effectiveness and safety of endocrine therapy, with or without targeted therapy, for patients with advanced metastatic breast cancer. This study concluded that the use of endocrine therapy and targeted therapy is safe for use in patients over 65.  Some background There are several treatment...

Read More

Is abemaciclib combined with fulvestrant effective in women with HR positive advanced breast cancer?

Posted by on Jul 15, 2017 in Breast cancer | 0 comments

In a nutshell This study aimed to compare the effectiveness of the combination of fulvestrant (Faslodex) and abemaciclib to fulvestrant alone in patients with advanced breast cancer. This study concluded that the combination of fulvestrant and abemaciclib had improved outcomes for patients when compared to fulvestrant alone.  Some background...

Read More

Comparing the effects of combined PI3K inhibitor/endocrine therapy versus endocrine therapy alone in ER-positive breast cancer

Posted by on Apr 3, 2017 in Breast cancer | 0 comments

In a nutshell This study investigated whether the addition of the PI3K inhibitor pictilisib (Stemolecule GDC-0941) can increase the anti-tumor effects of anastrozole (Arimidex) in patients with estrogen receptor-positive (ER-positive) primary breast cancer (BC). Combined treatment with pictilisib (PIC)...

Read More

Is paclitaxel more effective when combined with bevacizumab in metastatic breast cancer?

Posted by on Oct 3, 2016 in Breast cancer | 0 comments

In a nutshell This study investigated whether paclitaxel (Taxol) alone, or paclitaxel combined with bevacizumab (Avastin), had better outcomes in treating metastatic breast cancer. The authors found that paclitaxel with bevacizumab combination resulted in much better overall survival times (time from treatment until death from any cause)...

Read More

Using paclitaxel, capecitabine and bevacizumab together to treat triple-negative metastatic breast cancer

Posted by on Sep 26, 2016 in Breast cancer | 0 comments

In a nutshell This study examined whether a combination of paclitaxel, capecitabine, and bevacizumab was safe and effective in treating triple-negative, locally-advanced metastatic breast cancer. The three drugs taken together were safe and highly effective in treating these patients. Some background In recent years, many new...

Read More